Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2002-02

AUTHORS

Debabrata Mukherjee, Eric J Topol

ABSTRACT

Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological studies raise significant concern about the potential prothrombotic effect of this class of drugs. Two recent studies with a newer, more selective COX-2 inhibitor have added to the already existing concern about the cardiovascular safety of these agents. The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors. More... »

PAGES

8

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/ar609

DOI

http://dx.doi.org/10.1186/ar609

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052654384

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12716442


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dogs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoenzymes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostaglandin-Endoperoxide Synthases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rabbits", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombosis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Michigan\u2013Ann Arbor", 
          "id": "https://www.grid.ac/institutes/grid.214458.e", 
          "name": [
            "Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Debabrata", 
        "id": "sg:person.01134263324.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134263324.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic", 
          "id": "https://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Provost and Chief Academic Officer, Chairman, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F 25, 9500 Euclid Avenue, 44195, Cleveland, Ohio, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Topol", 
        "givenName": "Eric J", 
        "id": "sg:person.0731336524.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731336524.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1161/hc4401.100078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005604484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.96.1.272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009277940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.1.601", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009278303"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2296-3-10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011170596", 
          "https://doi.org/10.1186/1471-2296-3-10"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.97.18.10197", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012407146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)07370-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017122397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.102.8.840", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028122145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)11131-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028780946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200011233432103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030163021"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/hc3301.092790", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034784189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.284.10.1247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038199738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.286.8.954", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039930398"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.1068711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043103584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s000110050284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045689638", 
          "https://doi.org/10.1007/s000110050284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci11334", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063416038"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074362730", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075108121", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077328484", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078324262", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-02", 
    "datePublishedReg": "2002-02-01", 
    "description": "Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological studies raise significant concern about the potential prothrombotic effect of this class of drugs. Two recent studies with a newer, more selective COX-2 inhibitor have added to the already existing concern about the cardiovascular safety of these agents. The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/ar609", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors", 
    "pagination": "8", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "facf619cc150b00445b971b588f062768962475bbdfba41195e7a7c8eef2dfaf"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12716442"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/ar609"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052654384"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/ar609", 
      "https://app.dimensions.ai/details/publication/pub.1052654384"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000516.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Far609"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/ar609'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/ar609'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/ar609'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/ar609'


 

This table displays all metadata directly associated to this object as RDF triples.

194 TRIPLES      21 PREDICATES      63 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/ar609 schema:about N01f86252db5842d3a032506e42957e10
2 N062883387d7b49d29685cefc1462cb25
3 N0ca7347db6964cc69e489e159dd6cbb7
4 N11f1ecac864345639ae4590ca689de5d
5 N18bb336cd7a243a58be167dc00321753
6 N200ec748c3bb42c694fa4d96ea8c9b12
7 N220788fe21414ac09dc125f6c150daab
8 N25941d3d67be469d864f40c379d788ff
9 N573fec5a522b499fadf8eefd91b16f53
10 N5a7d683f012f4bf4b21552cff679c91a
11 N642b32b0a2eb44c4aa6a6347fea8d2c0
12 N6d644f6360a347d3a6dc6e7003e42102
13 N728b2d7c215f4a1691bc173ed1cf0b78
14 N90f8e478670041aca4488faeac0862a8
15 Nf86fa36011c44125be0887ec24d473de
16 anzsrc-for:11
17 anzsrc-for:1115
18 schema:author Nf6d8ec05ac274414b9b2d435da306591
19 schema:citation sg:pub.10.1007/s000110050284
20 sg:pub.10.1186/1471-2296-3-10
21 https://app.dimensions.ai/details/publication/pub.1074362730
22 https://app.dimensions.ai/details/publication/pub.1075108121
23 https://app.dimensions.ai/details/publication/pub.1077328484
24 https://app.dimensions.ai/details/publication/pub.1078324262
25 https://doi.org/10.1001/jama.284.10.1247
26 https://doi.org/10.1001/jama.286.8.954
27 https://doi.org/10.1016/s0140-6736(02)07370-1
28 https://doi.org/10.1016/s0140-6736(02)11131-7
29 https://doi.org/10.1056/nejm200011233432103
30 https://doi.org/10.1073/pnas.96.1.272
31 https://doi.org/10.1073/pnas.97.18.10197
32 https://doi.org/10.1074/jbc.272.1.601
33 https://doi.org/10.1126/science.1068711
34 https://doi.org/10.1161/01.cir.102.8.840
35 https://doi.org/10.1161/hc3301.092790
36 https://doi.org/10.1161/hc4401.100078
37 https://doi.org/10.1172/jci11334
38 schema:datePublished 2002-02
39 schema:datePublishedReg 2002-02-01
40 schema:description Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological studies raise significant concern about the potential prothrombotic effect of this class of drugs. Two recent studies with a newer, more selective COX-2 inhibitor have added to the already existing concern about the cardiovascular safety of these agents. The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree true
44 schema:isPartOf N1eed340b41e34df58e04b849e76a7811
45 N9fdcec9ee8834eaeb8fdbfbb6ae0df99
46 sg:journal.1297499
47 schema:name Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
48 schema:pagination 8
49 schema:productId N1996b1fbd3334434a07996aa95c0d09f
50 N32642f21b719419683f68e8e42be69c2
51 N3ac99cc69e4847aaa51e851929fee769
52 N8cd2c6a49769409d9f1011c24e606a50
53 Na831518e559e400c8eedb129f7f0fab7
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052654384
55 https://doi.org/10.1186/ar609
56 schema:sdDatePublished 2019-04-10T19:09
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Nd2da8f8cafe44df5a30127ac2a01c908
59 schema:url http://link.springer.com/10.1186%2Far609
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N01f86252db5842d3a032506e42957e10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Cyclooxygenase Inhibitors
65 rdf:type schema:DefinedTerm
66 N062883387d7b49d29685cefc1462cb25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Isoenzymes
68 rdf:type schema:DefinedTerm
69 N0ca7347db6964cc69e489e159dd6cbb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Rabbits
71 rdf:type schema:DefinedTerm
72 N11f1ecac864345639ae4590ca689de5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Humans
74 rdf:type schema:DefinedTerm
75 N18bb336cd7a243a58be167dc00321753 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Clinical Trials as Topic
77 rdf:type schema:DefinedTerm
78 N1996b1fbd3334434a07996aa95c0d09f schema:name doi
79 schema:value 10.1186/ar609
80 rdf:type schema:PropertyValue
81 N1eed340b41e34df58e04b849e76a7811 schema:issueNumber 1
82 rdf:type schema:PublicationIssue
83 N200ec748c3bb42c694fa4d96ea8c9b12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Mice
85 rdf:type schema:DefinedTerm
86 N220788fe21414ac09dc125f6c150daab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Risk Factors
88 rdf:type schema:DefinedTerm
89 N25941d3d67be469d864f40c379d788ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Animals
91 rdf:type schema:DefinedTerm
92 N32642f21b719419683f68e8e42be69c2 schema:name readcube_id
93 schema:value facf619cc150b00445b971b588f062768962475bbdfba41195e7a7c8eef2dfaf
94 rdf:type schema:PropertyValue
95 N3ac99cc69e4847aaa51e851929fee769 schema:name nlm_unique_id
96 schema:value 101154438
97 rdf:type schema:PropertyValue
98 N573fec5a522b499fadf8eefd91b16f53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Dogs
100 rdf:type schema:DefinedTerm
101 N5a7d683f012f4bf4b21552cff679c91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Prostaglandin-Endoperoxide Synthases
103 rdf:type schema:DefinedTerm
104 N642b32b0a2eb44c4aa6a6347fea8d2c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Cyclooxygenase 2 Inhibitors
106 rdf:type schema:DefinedTerm
107 N6d644f6360a347d3a6dc6e7003e42102 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Cardiovascular Diseases
109 rdf:type schema:DefinedTerm
110 N728b2d7c215f4a1691bc173ed1cf0b78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Membrane Proteins
112 rdf:type schema:DefinedTerm
113 N8cd2c6a49769409d9f1011c24e606a50 schema:name dimensions_id
114 schema:value pub.1052654384
115 rdf:type schema:PropertyValue
116 N8d04919f2f204217a7e08d6d51155e5d rdf:first sg:person.0731336524.18
117 rdf:rest rdf:nil
118 N90f8e478670041aca4488faeac0862a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Thrombosis
120 rdf:type schema:DefinedTerm
121 N9fdcec9ee8834eaeb8fdbfbb6ae0df99 schema:volumeNumber 5
122 rdf:type schema:PublicationVolume
123 Na831518e559e400c8eedb129f7f0fab7 schema:name pubmed_id
124 schema:value 12716442
125 rdf:type schema:PropertyValue
126 Nd2da8f8cafe44df5a30127ac2a01c908 schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 Nf6d8ec05ac274414b9b2d435da306591 rdf:first sg:person.01134263324.09
129 rdf:rest N8d04919f2f204217a7e08d6d51155e5d
130 Nf86fa36011c44125be0887ec24d473de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Cyclooxygenase 2
132 rdf:type schema:DefinedTerm
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
137 schema:name Pharmacology and Pharmaceutical Sciences
138 rdf:type schema:DefinedTerm
139 sg:journal.1297499 schema:issn 1478-6354
140 1478-6362
141 schema:name Arthritis Research & Therapy
142 rdf:type schema:Periodical
143 sg:person.01134263324.09 schema:affiliation https://www.grid.ac/institutes/grid.214458.e
144 schema:familyName Mukherjee
145 schema:givenName Debabrata
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134263324.09
147 rdf:type schema:Person
148 sg:person.0731336524.18 schema:affiliation https://www.grid.ac/institutes/grid.239578.2
149 schema:familyName Topol
150 schema:givenName Eric J
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731336524.18
152 rdf:type schema:Person
153 sg:pub.10.1007/s000110050284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045689638
154 https://doi.org/10.1007/s000110050284
155 rdf:type schema:CreativeWork
156 sg:pub.10.1186/1471-2296-3-10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011170596
157 https://doi.org/10.1186/1471-2296-3-10
158 rdf:type schema:CreativeWork
159 https://app.dimensions.ai/details/publication/pub.1074362730 schema:CreativeWork
160 https://app.dimensions.ai/details/publication/pub.1075108121 schema:CreativeWork
161 https://app.dimensions.ai/details/publication/pub.1077328484 schema:CreativeWork
162 https://app.dimensions.ai/details/publication/pub.1078324262 schema:CreativeWork
163 https://doi.org/10.1001/jama.284.10.1247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038199738
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1001/jama.286.8.954 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039930398
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1016/s0140-6736(02)07370-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017122397
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/s0140-6736(02)11131-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028780946
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1056/nejm200011233432103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030163021
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1073/pnas.96.1.272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009277940
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1073/pnas.97.18.10197 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012407146
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1074/jbc.272.1.601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009278303
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1126/science.1068711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043103584
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1161/01.cir.102.8.840 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028122145
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1161/hc3301.092790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034784189
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1161/hc4401.100078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005604484
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1172/jci11334 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063416038
188 rdf:type schema:CreativeWork
189 https://www.grid.ac/institutes/grid.214458.e schema:alternateName University of Michigan–Ann Arbor
190 schema:name Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
191 rdf:type schema:Organization
192 https://www.grid.ac/institutes/grid.239578.2 schema:alternateName Cleveland Clinic
193 schema:name Provost and Chief Academic Officer, Chairman, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F 25, 9500 Euclid Avenue, 44195, Cleveland, Ohio, USA
194 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...